IMG_1591-01.jpeg

ABOUT

 

“Johns Hopkins is deeply committed to exploring innovative treatments for our patients. Our scientists have shown that psychedelics have real potential as medicine, and this new center will help us explore that potential.”
- Paul B. Rothman, M.D., Dean of the Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine. 

Scientists today are entering a new era of studying a truly unique class of pharmacological compounds known as psychedelics. Although research with these compounds was first started in the 1950s and ‘60s, it abruptly ended in the early 1970s in response to unfavorable media coverage, resulting in misperceptions of risk and highly restrictive regulations.

After a decades-long hiatus, in 2000 our research group at Johns Hopkins was the first to obtain regulatory approval in the United States to reinitiate research with psychedelics in healthy volunteers. Our 2006 publication on the safety and enduring positive effects of a single dose of psilocybin is widely considered the landmark study that sparked a renewal of psychedelic research world-wide.

Since that time, we have published further groundbreaking studies in more than 60 peer-reviewed articles in respected scientific journals. This makes Johns Hopkins the leading psychedelic research institution in the U.S., and among the few leading groups worldwide. Our research has demonstrated therapeutic effects in people who suffer a range of challenging conditions including addiction (smoking, alcohol, other drugs of abuse), existential distress caused by life-threatening disease, and treatment-resistant depression. Studying healthy volunteers has also advanced our understanding of the enduring positive effects of psilocybin and provided unique insight into neurophysiological mechanisms of action, with implications for understanding consciousness and optimizing therapeutic and non-therapeutic enduring positive effects.

At the Center for Psychedelic and Consciousness Research, researchers will focus on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health. Upcoming studies will determine the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post-traumatic stress disorder (PTSD), post-treatment Lyme disease syndrome (formerly known as chronic Lyme disease), anorexia nervosa and alcohol use in people with major depression. The researchers hope to create precision medicine treatments tailored to the specific needs of individual patients. 

 
 
 
 

MEDIA

Browse featured articles below to learn more about our findings, or click here to see what others are saying about our research

 
 
 

PROJECTS

 
 
 
 

MEET THE TEAM

 
 
 

CONTACT US

Behavioral Pharmacology Research Unit
5510 Nathan Shock Drive
Baltimore, MD 21224

Phone: 410-550-2253

Directions & Campus Map

 
Name
Name